MANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of ...

The first launch was in the Philippines ... programme was rushed, while Sanofi Pasteur representatives stood by the safety and efficacy of Dengvaxia. In the meantime, Sanofi held an analyst ...

MANILA, Philippines — The Court of Appeals (CA) has denied the motion for reconsideration filed by French drugmaker Sanofi ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past.

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and drug shortages have prompted a call for industrial action in the company ...

Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...